| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Primary Myelofibrosis | 244 | 2024 | 915 | 50.200 |
Why?
|
| Polycythemia Vera | 88 | 2024 | 268 | 22.200 |
Why?
|
| Janus Kinase 2 | 151 | 2024 | 754 | 20.590 |
Why?
|
| Pyrazoles | 112 | 2024 | 1544 | 18.780 |
Why?
|
| Myeloproliferative Disorders | 112 | 2024 | 881 | 18.140 |
Why?
|
| Thrombocythemia, Essential | 53 | 2023 | 179 | 17.110 |
Why?
|
| Protein Kinase Inhibitors | 135 | 2023 | 4964 | 10.640 |
Why?
|
| Nitriles | 119 | 2024 | 944 | 10.270 |
Why?
|
| Pyrimidines | 195 | 2024 | 3664 | 10.260 |
Why?
|
| Anemia | 38 | 2024 | 730 | 10.150 |
Why?
|
| Janus Kinase Inhibitors | 20 | 2023 | 74 | 8.790 |
Why?
|
| Janus Kinases | 40 | 2021 | 175 | 6.690 |
Why?
|
| Janus Kinase 1 | 29 | 2022 | 125 | 6.680 |
Why?
|
| Mastocytosis, Systemic | 26 | 2021 | 119 | 5.000 |
Why?
|
| Antineoplastic Agents | 126 | 2022 | 14653 | 4.290 |
Why?
|
| Splenomegaly | 25 | 2023 | 173 | 3.760 |
Why?
|
| Thrombocytopenia | 22 | 2023 | 872 | 3.740 |
Why?
|
| Thrombosis | 16 | 2023 | 755 | 3.700 |
Why?
|
| Benzamides | 73 | 2024 | 1882 | 3.550 |
Why?
|
| Bone Marrow | 52 | 2023 | 2446 | 3.500 |
Why?
|
| Humans | 652 | 2024 | 271941 | 3.480 |
Why?
|
| Mutation | 105 | 2024 | 15941 | 3.450 |
Why?
|
| Hydroxyurea | 18 | 2022 | 224 | 3.430 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 66 | 2021 | 2634 | 3.240 |
Why?
|
| Thalidomide | 16 | 2017 | 595 | 3.000 |
Why?
|
| Hypereosinophilic Syndrome | 16 | 2022 | 86 | 2.990 |
Why?
|
| Aged | 299 | 2024 | 73494 | 2.850 |
Why?
|
| Leukemia, Myeloid, Acute | 69 | 2022 | 7258 | 2.800 |
Why?
|
| Treatment Outcome | 191 | 2024 | 33874 | 2.760 |
Why?
|
| Middle Aged | 320 | 2024 | 90427 | 2.570 |
Why?
|
| Interferon-alpha | 27 | 2020 | 964 | 2.550 |
Why?
|
| Aged, 80 and over | 173 | 2022 | 31060 | 2.490 |
Why?
|
| Blast Crisis | 19 | 2021 | 587 | 2.370 |
Why?
|
| Spleen | 26 | 2020 | 732 | 2.290 |
Why?
|
| Male | 311 | 2024 | 128995 | 2.200 |
Why?
|
| Hematologic Neoplasms | 28 | 2022 | 1950 | 2.100 |
Why?
|
| Piperazines | 59 | 2013 | 2152 | 2.070 |
Why?
|
| Adult | 253 | 2024 | 81889 | 2.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 82 | 2023 | 16610 | 2.030 |
Why?
|
| Female | 318 | 2024 | 149187 | 2.020 |
Why?
|
| Leukemia, Myeloid | 31 | 2019 | 994 | 1.990 |
Why?
|
| Prognosis | 108 | 2023 | 22550 | 1.950 |
Why?
|
| Philadelphia Chromosome | 25 | 2020 | 836 | 1.910 |
Why?
|
| Thrombocytosis | 8 | 2021 | 142 | 1.810 |
Why?
|
| Myelodysplastic Syndromes | 47 | 2024 | 3148 | 1.800 |
Why?
|
| Mast Cells | 15 | 2021 | 231 | 1.760 |
Why?
|
| Proto-Oncogene Proteins c-kit | 17 | 2021 | 490 | 1.750 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 7 | 2021 | 120 | 1.720 |
Why?
|
| Imatinib Mesylate | 66 | 2019 | 1690 | 1.700 |
Why?
|
| Point Mutation | 14 | 2015 | 793 | 1.660 |
Why?
|
| Mastocytosis | 7 | 2021 | 21 | 1.550 |
Why?
|
| Bridged-Ring Compounds | 6 | 2022 | 180 | 1.550 |
Why?
|
| Arsenicals | 12 | 2021 | 204 | 1.480 |
Why?
|
| Prednisone | 8 | 2017 | 1036 | 1.460 |
Why?
|
| Polyethylene Glycols | 13 | 2020 | 642 | 1.440 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 8 | 2021 | 121 | 1.430 |
Why?
|
| Fusion Proteins, bcr-abl | 25 | 2023 | 1143 | 1.410 |
Why?
|
| Bone Marrow Neoplasms | 7 | 2023 | 128 | 1.350 |
Why?
|
| Telomerase | 5 | 2022 | 543 | 1.330 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 6 | 2015 | 130 | 1.320 |
Why?
|
| Follow-Up Studies | 59 | 2021 | 15269 | 1.310 |
Why?
|
| Immunologic Factors | 9 | 2017 | 669 | 1.310 |
Why?
|
| Cell Transformation, Neoplastic | 19 | 2019 | 2472 | 1.300 |
Why?
|
| Molecular Targeted Therapy | 18 | 2021 | 2400 | 1.290 |
Why?
|
| Recombinant Proteins | 18 | 2023 | 3072 | 1.240 |
Why?
|
| Disease Progression | 42 | 2022 | 6910 | 1.230 |
Why?
|
| Histone Deacetylase Inhibitors | 7 | 2022 | 621 | 1.230 |
Why?
|
| Quality of Life | 26 | 2024 | 4749 | 1.230 |
Why?
|
| Survival Analysis | 47 | 2021 | 9325 | 1.210 |
Why?
|
| Blood Platelets | 4 | 2018 | 684 | 1.190 |
Why?
|
| Thiazoles | 13 | 2021 | 725 | 1.170 |
Why?
|
| Drug Design | 5 | 2017 | 378 | 1.150 |
Why?
|
| Leukemia, Mast-Cell | 3 | 2017 | 15 | 1.130 |
Why?
|
| Cytarabine | 30 | 2021 | 2014 | 1.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 23 | 2022 | 6987 | 1.120 |
Why?
|
| Enzyme Inhibitors | 12 | 2013 | 1966 | 1.120 |
Why?
|
| Young Adult | 66 | 2024 | 22127 | 1.110 |
Why?
|
| Oncogene Proteins, Fusion | 8 | 2018 | 802 | 1.110 |
Why?
|
| Double-Blind Method | 18 | 2024 | 2619 | 1.100 |
Why?
|
| Chromosome Aberrations | 19 | 2022 | 2034 | 1.070 |
Why?
|
| Eosinophilia | 4 | 2018 | 188 | 1.060 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 13 | 2020 | 529 | 1.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 12 | 2022 | 499 | 1.040 |
Why?
|
| Survival Rate | 56 | 2021 | 12533 | 1.040 |
Why?
|
| Neoplasm Proteins | 10 | 2021 | 3363 | 1.040 |
Why?
|
| Retrospective Studies | 62 | 2024 | 39800 | 1.020 |
Why?
|
| Platelet Count | 12 | 2022 | 491 | 1.020 |
Why?
|
| Remission Induction | 51 | 2020 | 3645 | 1.010 |
Why?
|
| Pyrroles | 7 | 2021 | 592 | 0.990 |
Why?
|
| Protein-Tyrosine Kinases | 29 | 2021 | 1842 | 0.990 |
Why?
|
| Receptors, Thrombopoietin | 12 | 2021 | 79 | 0.990 |
Why?
|
| Neoplasms, Second Primary | 7 | 2020 | 1388 | 0.960 |
Why?
|
| Calreticulin | 10 | 2019 | 87 | 0.950 |
Why?
|
| Leukemia | 17 | 2020 | 1721 | 0.940 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 7 | 2018 | 461 | 0.910 |
Why?
|
| Signal Transduction | 39 | 2022 | 12223 | 0.910 |
Why?
|
| Azacitidine | 13 | 2018 | 1219 | 0.890 |
Why?
|
| Biomarkers | 21 | 2022 | 5114 | 0.870 |
Why?
|
| Lymphoma | 7 | 2019 | 1514 | 0.870 |
Why?
|
| Quinazolines | 6 | 2022 | 953 | 0.860 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2023 | 100 | 0.860 |
Why?
|
| Randomized Controlled Trials as Topic | 13 | 2023 | 2679 | 0.840 |
Why?
|
| Phosphates | 1 | 2023 | 194 | 0.840 |
Why?
|
| Pyridazines | 5 | 2019 | 319 | 0.830 |
Why?
|
| Sulfonamides | 17 | 2023 | 1919 | 0.830 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 6 | 2019 | 842 | 0.830 |
Why?
|
| Blood Cell Count | 5 | 2017 | 234 | 0.830 |
Why?
|
| Anemia, Aplastic | 1 | 2024 | 233 | 0.820 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 5 | 2017 | 114 | 0.820 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 3 | 2018 | 189 | 0.820 |
Why?
|
| Drug Administration Schedule | 32 | 2020 | 3540 | 0.820 |
Why?
|
| Stem Cell Transplantation | 9 | 2018 | 1423 | 0.800 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 4 | 2013 | 57 | 0.800 |
Why?
|
| Alleles | 14 | 2020 | 2599 | 0.790 |
Why?
|
| Clinical Trials as Topic | 22 | 2022 | 3853 | 0.770 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2019 | 1335 | 0.760 |
Why?
|
| Antibodies, Monoclonal, Humanized | 17 | 2020 | 3393 | 0.750 |
Why?
|
| Imidazoles | 7 | 2019 | 1056 | 0.740 |
Why?
|
| Polycythemia | 5 | 2024 | 65 | 0.730 |
Why?
|
| Administration, Oral | 16 | 2021 | 1620 | 0.720 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2019 | 352 | 0.720 |
Why?
|
| Danazol | 4 | 2024 | 5 | 0.710 |
Why?
|
| Pyrrolidines | 7 | 2023 | 114 | 0.710 |
Why?
|
| Leukemia, Promyelocytic, Acute | 8 | 2021 | 439 | 0.710 |
Why?
|
| Community Health Services | 1 | 2021 | 129 | 0.710 |
Why?
|
| Carbamates | 1 | 2020 | 81 | 0.710 |
Why?
|
| Autoimmune Diseases | 3 | 2016 | 433 | 0.700 |
Why?
|
| Hepcidins | 4 | 2024 | 34 | 0.700 |
Why?
|
| Risk Factors | 31 | 2023 | 18047 | 0.700 |
Why?
|
| Withholding Treatment | 2 | 2019 | 155 | 0.700 |
Why?
|
| Erythrocyte Transfusion | 3 | 2013 | 211 | 0.690 |
Why?
|
| Dasatinib | 16 | 2020 | 881 | 0.680 |
Why?
|
| Immunotherapy | 7 | 2021 | 3546 | 0.680 |
Why?
|
| Animals | 63 | 2022 | 62823 | 0.670 |
Why?
|
| Leukemia, Neutrophilic, Chronic | 2 | 2013 | 13 | 0.670 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 2 | 2020 | 154 | 0.660 |
Why?
|
| Organ Size | 11 | 2020 | 727 | 0.650 |
Why?
|
| Drug Resistance | 6 | 2015 | 615 | 0.650 |
Why?
|
| Drug Therapy, Combination | 11 | 2023 | 2366 | 0.650 |
Why?
|
| Sirolimus | 4 | 2012 | 833 | 0.640 |
Why?
|
| Disease-Free Survival | 42 | 2021 | 10259 | 0.640 |
Why?
|
| Mastocytosis, Cutaneous | 1 | 2018 | 6 | 0.630 |
Why?
|
| Apoptosis | 31 | 2021 | 7837 | 0.620 |
Why?
|
| Oxides | 9 | 2021 | 212 | 0.620 |
Why?
|
| Ki-1 Antigen | 1 | 2019 | 186 | 0.620 |
Why?
|
| Hepatomegaly | 2 | 2015 | 72 | 0.610 |
Why?
|
| Monocytes | 4 | 2019 | 789 | 0.610 |
Why?
|
| Anemia, Sideroblastic | 3 | 2021 | 58 | 0.600 |
Why?
|
| Adolescent | 68 | 2023 | 32687 | 0.590 |
Why?
|
| Hemorrhage | 3 | 2017 | 747 | 0.590 |
Why?
|
| Isocitrate Dehydrogenase | 3 | 2020 | 520 | 0.590 |
Why?
|
| Angiogenesis Inhibitors | 6 | 2013 | 1265 | 0.580 |
Why?
|
| Plateletpheresis | 1 | 2017 | 11 | 0.580 |
Why?
|
| Haptoglobins | 1 | 2017 | 27 | 0.580 |
Why?
|
| Anemia, Refractory | 3 | 2016 | 40 | 0.580 |
Why?
|
| Reticulocytes | 1 | 2017 | 60 | 0.570 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 376 | 0.570 |
Why?
|
| Isonicotinic Acids | 1 | 2016 | 1 | 0.570 |
Why?
|
| Social Media | 1 | 2021 | 211 | 0.560 |
Why?
|
| Neoplasms | 16 | 2023 | 15928 | 0.550 |
Why?
|
| STAT Transcription Factors | 7 | 2021 | 80 | 0.550 |
Why?
|
| Proto-Oncogene Proteins | 11 | 2020 | 2624 | 0.550 |
Why?
|
| Lymphoma, T-Cell | 6 | 2009 | 369 | 0.540 |
Why?
|
| Chromosomes, Human, Pair 5 | 3 | 2013 | 274 | 0.540 |
Why?
|
| Azetidines | 1 | 2016 | 88 | 0.540 |
Why?
|
| Blood Proteins | 1 | 2017 | 301 | 0.540 |
Why?
|
| Cytokines | 15 | 2021 | 2841 | 0.540 |
Why?
|
| Erythrocyte Indices | 2 | 2021 | 24 | 0.540 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 12 | 2022 | 2474 | 0.530 |
Why?
|
| Antimetabolites, Antineoplastic | 8 | 2019 | 1351 | 0.530 |
Why?
|
| Leukocyte Count | 11 | 2018 | 738 | 0.530 |
Why?
|
| Erythrocytes | 3 | 2023 | 340 | 0.530 |
Why?
|
| Dose-Response Relationship, Drug | 26 | 2021 | 5105 | 0.520 |
Why?
|
| Repressor Proteins | 4 | 2024 | 1730 | 0.520 |
Why?
|
| Genomics | 2 | 2017 | 2830 | 0.520 |
Why?
|
| Mutant Proteins | 3 | 2013 | 235 | 0.520 |
Why?
|
| Drugs, Investigational | 5 | 2017 | 129 | 0.520 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2015 | 62 | 0.510 |
Why?
|
| Maximum Tolerated Dose | 10 | 2017 | 1323 | 0.510 |
Why?
|
| Bone Marrow Examination | 8 | 2017 | 151 | 0.510 |
Why?
|
| Chromosome Deletion | 4 | 2017 | 1055 | 0.500 |
Why?
|
| Kaplan-Meier Estimate | 20 | 2020 | 6270 | 0.500 |
Why?
|
| Serum Amyloid P-Component | 3 | 2022 | 31 | 0.500 |
Why?
|
| Veratrum Alkaloids | 1 | 2015 | 35 | 0.500 |
Why?
|
| Endothelial Growth Factors | 4 | 2003 | 234 | 0.490 |
Why?
|
| Prospective Studies | 15 | 2022 | 13402 | 0.490 |
Why?
|
| Disease Management | 7 | 2018 | 1111 | 0.480 |
Why?
|
| STAT5 Transcription Factor | 5 | 2016 | 227 | 0.480 |
Why?
|
| Lymphokines | 4 | 2003 | 317 | 0.480 |
Why?
|
| Practice Guidelines as Topic | 8 | 2016 | 2429 | 0.480 |
Why?
|
| Hedgehog Proteins | 3 | 2022 | 441 | 0.480 |
Why?
|
| Antibodies, Neoplasm | 6 | 2009 | 275 | 0.470 |
Why?
|
| Fibrosis | 8 | 2023 | 747 | 0.470 |
Why?
|
| Surveys and Questionnaires | 5 | 2021 | 5929 | 0.470 |
Why?
|
| Pyridines | 7 | 2018 | 1312 | 0.470 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 876 | 0.470 |
Why?
|
| Antibodies, Monoclonal | 18 | 2017 | 4496 | 0.470 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2015 | 196 | 0.460 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2013 | 85 | 0.460 |
Why?
|
| Fibroblasts | 2 | 2019 | 1670 | 0.450 |
Why?
|
| Karyotype | 6 | 2022 | 237 | 0.450 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2014 | 92 | 0.450 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2014 | 36 | 0.450 |
Why?
|
| Genetic Association Studies | 3 | 2017 | 1095 | 0.450 |
Why?
|
| Pharmaceutical Preparations | 1 | 2015 | 157 | 0.450 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2002 | 685 | 0.450 |
Why?
|
| Transplantation, Homologous | 11 | 2021 | 3036 | 0.440 |
Why?
|
| Risk Assessment | 12 | 2022 | 6883 | 0.440 |
Why?
|
| Acute Disease | 26 | 2020 | 2514 | 0.440 |
Why?
|
| DNA Mutational Analysis | 14 | 2019 | 2365 | 0.440 |
Why?
|
| STAT3 Transcription Factor | 9 | 2022 | 1146 | 0.440 |
Why?
|
| Proline | 1 | 2013 | 127 | 0.430 |
Why?
|
| Niacinamide | 2 | 2014 | 427 | 0.430 |
Why?
|
| Skin | 2 | 2018 | 1284 | 0.430 |
Why?
|
| Proteins | 1 | 2021 | 2058 | 0.430 |
Why?
|
| Drug Resistance, Neoplasm | 31 | 2020 | 5421 | 0.430 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2021 | 9101 | 0.420 |
Why?
|
| Splenic Neoplasms | 2 | 2013 | 125 | 0.420 |
Why?
|
| Carbazoles | 2 | 2009 | 92 | 0.410 |
Why?
|
| Translocation, Genetic | 8 | 2021 | 1288 | 0.410 |
Why?
|
| Splenectomy | 1 | 2013 | 168 | 0.410 |
Why?
|
| Erythropoietin | 5 | 2023 | 219 | 0.410 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2015 | 382 | 0.410 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2013 | 126 | 0.410 |
Why?
|
| Genes, abl | 5 | 2008 | 120 | 0.410 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2022 | 1547 | 0.400 |
Why?
|
| Cladribine | 5 | 2021 | 253 | 0.400 |
Why?
|
| Megakaryocytes | 5 | 2019 | 131 | 0.390 |
Why?
|
| Biomarkers, Tumor | 13 | 2020 | 10750 | 0.390 |
Why?
|
| Salvage Therapy | 16 | 2017 | 2119 | 0.390 |
Why?
|
| Bone Marrow Cells | 8 | 2019 | 983 | 0.390 |
Why?
|
| Prevalence | 8 | 2023 | 3426 | 0.390 |
Why?
|
| United States | 12 | 2022 | 16053 | 0.390 |
Why?
|
| Idarubicin | 10 | 2010 | 459 | 0.390 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 11 | 2020 | 2903 | 0.380 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 420 | 0.380 |
Why?
|
| Phenylurea Compounds | 2 | 2014 | 600 | 0.380 |
Why?
|
| High-Throughput Nucleotide Sequencing | 8 | 2019 | 2357 | 0.380 |
Why?
|
| Mice | 40 | 2022 | 36054 | 0.380 |
Why?
|
| Caspase 3 | 8 | 2016 | 481 | 0.370 |
Why?
|
| Comorbidity | 4 | 2021 | 2439 | 0.370 |
Why?
|
| Cohort Studies | 15 | 2022 | 9494 | 0.370 |
Why?
|
| Triazines | 2 | 2021 | 123 | 0.370 |
Why?
|
| Clinical Trials, Phase II as Topic | 6 | 2022 | 686 | 0.360 |
Why?
|
| Hemoglobins | 6 | 2023 | 485 | 0.360 |
Why?
|
| Combined Modality Therapy | 15 | 2019 | 9044 | 0.360 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2021 | 864 | 0.360 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 3 | 2021 | 996 | 0.360 |
Why?
|
| In Situ Hybridization, Fluorescence | 10 | 2020 | 2317 | 0.350 |
Why?
|
| Indoles | 4 | 2010 | 1034 | 0.350 |
Why?
|
| Mutation, Missense | 10 | 2018 | 1197 | 0.350 |
Why?
|
| Epigenesis, Genetic | 6 | 2021 | 1439 | 0.350 |
Why?
|
| Glutathione | 2 | 2009 | 377 | 0.340 |
Why?
|
| Time Factors | 29 | 2020 | 13130 | 0.340 |
Why?
|
| Drug Screening Assays, Antitumor | 8 | 2010 | 569 | 0.340 |
Why?
|
| Arabinonucleosides | 5 | 2016 | 458 | 0.340 |
Why?
|
| Tumor Cells, Cultured | 20 | 2022 | 5804 | 0.340 |
Why?
|
| Interferons | 3 | 2022 | 301 | 0.330 |
Why?
|
| Immunosuppressive Agents | 4 | 2022 | 1442 | 0.330 |
Why?
|
| DNA-Binding Proteins | 7 | 2021 | 5067 | 0.330 |
Why?
|
| Peptides | 4 | 2024 | 1529 | 0.330 |
Why?
|
| Adenine Nucleotides | 5 | 2016 | 365 | 0.330 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2019 | 5755 | 0.320 |
Why?
|
| Fatigue | 8 | 2017 | 1280 | 0.320 |
Why?
|
| Amino Acid Substitution | 7 | 2018 | 661 | 0.320 |
Why?
|
| Proportional Hazards Models | 15 | 2019 | 5118 | 0.320 |
Why?
|
| Cytosine | 3 | 2004 | 157 | 0.320 |
Why?
|
| Europe | 5 | 2019 | 659 | 0.320 |
Why?
|
| Flow Cytometry | 11 | 2020 | 3078 | 0.320 |
Why?
|
| Polymerase Chain Reaction | 14 | 2016 | 3512 | 0.320 |
Why?
|
| Activin Receptors, Type I | 3 | 2023 | 58 | 0.310 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2019 | 506 | 0.310 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2008 | 40 | 0.310 |
Why?
|
| Age Factors | 11 | 2019 | 5521 | 0.310 |
Why?
|
| Gene Frequency | 6 | 2017 | 1241 | 0.310 |
Why?
|
| Genes, p53 | 1 | 2012 | 1146 | 0.310 |
Why?
|
| Biological Products | 2 | 2022 | 316 | 0.300 |
Why?
|
| Aminoglycosides | 7 | 2016 | 235 | 0.300 |
Why?
|
| Mutation Rate | 2 | 2019 | 220 | 0.300 |
Why?
|
| Hematocrit | 3 | 2024 | 156 | 0.300 |
Why?
|
| Receptors, Cell Surface | 2 | 2002 | 911 | 0.300 |
Why?
|
| Blood Transfusion | 2 | 2024 | 583 | 0.300 |
Why?
|
| Referral and Consultation | 1 | 2013 | 940 | 0.300 |
Why?
|
| Benzimidazoles | 3 | 2019 | 442 | 0.300 |
Why?
|
| Tyrphostins | 1 | 2008 | 112 | 0.300 |
Why?
|
| Drug Synergism | 9 | 2018 | 1364 | 0.300 |
Why?
|
| Alemtuzumab | 7 | 2022 | 208 | 0.300 |
Why?
|
| Dioxygenases | 5 | 2020 | 171 | 0.290 |
Why?
|
| Cardiovascular Diseases | 4 | 2023 | 2307 | 0.290 |
Why?
|
| Rituximab | 9 | 2017 | 1588 | 0.280 |
Why?
|
| Consensus | 5 | 2016 | 1116 | 0.280 |
Why?
|
| World Health Organization | 6 | 2022 | 328 | 0.280 |
Why?
|
| C-Reactive Protein | 2 | 2022 | 567 | 0.280 |
Why?
|
| Phenotype | 9 | 2022 | 6516 | 0.280 |
Why?
|
| Penis | 1 | 2007 | 142 | 0.280 |
Why?
|
| Leukemia, Lymphoid | 4 | 2017 | 290 | 0.270 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 3 | 2005 | 122 | 0.270 |
Why?
|
| Tumor Necrosis Factor-alpha | 8 | 2006 | 1614 | 0.270 |
Why?
|
| Retreatment | 3 | 2016 | 447 | 0.270 |
Why?
|
| Recurrence | 17 | 2021 | 4887 | 0.270 |
Why?
|
| Diagnosis, Differential | 9 | 2023 | 4891 | 0.270 |
Why?
|
| Cause of Death | 1 | 2009 | 787 | 0.270 |
Why?
|
| Severity of Illness Index | 7 | 2019 | 4399 | 0.270 |
Why?
|
| Cell Line, Tumor | 22 | 2022 | 14881 | 0.270 |
Why?
|
| Chromosomes, Human | 4 | 2017 | 290 | 0.270 |
Why?
|
| Cytogenetic Analysis | 11 | 2017 | 574 | 0.260 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2015 | 503 | 0.260 |
Why?
|
| Genes, ras | 3 | 2019 | 681 | 0.250 |
Why?
|
| Interleukin-2 | 6 | 2007 | 891 | 0.250 |
Why?
|
| Gene Rearrangement | 3 | 2020 | 817 | 0.250 |
Why?
|
| Doxorubicin | 14 | 2020 | 3131 | 0.250 |
Why?
|
| Macrophages | 4 | 1999 | 1377 | 0.250 |
Why?
|
| Clinical Trials, Phase I as Topic | 4 | 2021 | 622 | 0.240 |
Why?
|
| Abnormal Karyotype | 3 | 2022 | 101 | 0.240 |
Why?
|
| Diarrhea | 6 | 2017 | 730 | 0.240 |
Why?
|
| Blotting, Western | 10 | 2014 | 3646 | 0.240 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 3 | 2013 | 191 | 0.230 |
Why?
|
| Allografts | 3 | 2021 | 684 | 0.230 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 1295 | 0.230 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 534 | 0.230 |
Why?
|
| Antigens, Neoplasm | 6 | 2008 | 1590 | 0.230 |
Why?
|
| Phosphorylation | 16 | 2014 | 4984 | 0.230 |
Why?
|
| Case-Control Studies | 8 | 2018 | 6236 | 0.230 |
Why?
|
| Interferon Type I | 1 | 2005 | 283 | 0.230 |
Why?
|
| Cell Cycle Proteins | 4 | 2021 | 2129 | 0.220 |
Why?
|
| Multicenter Studies as Topic | 2 | 2022 | 566 | 0.220 |
Why?
|
| Cacodylic Acid | 1 | 2003 | 9 | 0.220 |
Why?
|
| Placebos | 2 | 2015 | 446 | 0.220 |
Why?
|
| Herbicides | 1 | 2003 | 16 | 0.220 |
Why?
|
| Macrophage Activation | 2 | 1994 | 151 | 0.220 |
Why?
|
| Transcription Factors | 5 | 2023 | 5506 | 0.220 |
Why?
|
| Mice, SCID | 5 | 2019 | 1851 | 0.220 |
Why?
|
| Cyclophosphamide | 14 | 2020 | 3231 | 0.220 |
Why?
|
| Neovascularization, Pathologic | 5 | 2006 | 1599 | 0.220 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 2 | 2014 | 71 | 0.220 |
Why?
|
| Bone Marrow Diseases | 1 | 2024 | 187 | 0.220 |
Why?
|
| Transcriptome | 4 | 2021 | 1950 | 0.220 |
Why?
|
| Dexamethasone | 12 | 2020 | 1497 | 0.220 |
Why?
|
| Phlebotomy | 1 | 2023 | 26 | 0.210 |
Why?
|
| Predictive Value of Tests | 9 | 2020 | 4998 | 0.210 |
Why?
|
| Cell Proliferation | 12 | 2018 | 7302 | 0.210 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2005 | 271 | 0.210 |
Why?
|
| Hydrazines | 4 | 2021 | 214 | 0.210 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2018 | 4639 | 0.200 |
Why?
|
| Gene Expression | 4 | 2019 | 3689 | 0.200 |
Why?
|
| Models, Biological | 4 | 2019 | 3223 | 0.200 |
Why?
|
| Hematologic Agents | 2 | 2024 | 13 | 0.200 |
Why?
|
| Histiocytosis | 1 | 2022 | 56 | 0.200 |
Why?
|
| Biopsy | 7 | 2018 | 3544 | 0.200 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2022 | 115 | 0.200 |
Why?
|
| Sarcoma, Myeloid | 3 | 2008 | 94 | 0.200 |
Why?
|
| Receptors, Growth Factor | 1 | 2002 | 159 | 0.200 |
Why?
|
| Immunophenotyping | 8 | 2020 | 1732 | 0.200 |
Why?
|
| Poly(ADP-ribose) Polymerases | 3 | 2016 | 320 | 0.200 |
Why?
|
| Vidarabine | 6 | 2020 | 1383 | 0.200 |
Why?
|
| Cross-Over Studies | 4 | 2018 | 453 | 0.200 |
Why?
|
| Cholestyramine Resin | 1 | 2021 | 17 | 0.200 |
Why?
|
| Daunorubicin | 3 | 2020 | 313 | 0.200 |
Why?
|
| Transplantation Conditioning | 5 | 2022 | 2359 | 0.190 |
Why?
|
| RNA Splicing Factors | 1 | 2022 | 154 | 0.190 |
Why?
|
| Staurosporine | 2 | 2019 | 149 | 0.190 |
Why?
|
| Multiple Myeloma | 3 | 2014 | 2286 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2022 | 66 | 0.190 |
Why?
|
| Isochromosomes | 1 | 2021 | 55 | 0.190 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2001 | 58 | 0.190 |
Why?
|
| Emergencies | 1 | 2023 | 227 | 0.190 |
Why?
|
| Vincristine | 10 | 2017 | 1572 | 0.190 |
Why?
|
| beta 2-Microglobulin | 3 | 2007 | 189 | 0.190 |
Why?
|
| Warfarin | 1 | 2022 | 152 | 0.190 |
Why?
|
| Clone Cells | 8 | 2013 | 589 | 0.190 |
Why?
|
| Harringtonines | 3 | 2013 | 93 | 0.190 |
Why?
|
| Incidence | 3 | 2021 | 5861 | 0.190 |
Why?
|
| Hematology | 1 | 2022 | 99 | 0.180 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2001 | 155 | 0.180 |
Why?
|
| Chronic Disease | 10 | 2020 | 1853 | 0.180 |
Why?
|
| Everolimus | 4 | 2012 | 438 | 0.180 |
Why?
|
| RNA, Long Noncoding | 2 | 2018 | 619 | 0.180 |
Why?
|
| Risk | 4 | 2019 | 1950 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2020 | 10365 | 0.180 |
Why?
|
| Hematinics | 2 | 2013 | 109 | 0.180 |
Why?
|
| Hematopoiesis | 4 | 2022 | 608 | 0.180 |
Why?
|
| Sweet Syndrome | 1 | 2020 | 35 | 0.180 |
Why?
|
| Lysine | 1 | 2022 | 428 | 0.180 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2000 | 57 | 0.180 |
Why?
|
| Graft vs Host Disease | 2 | 2022 | 2804 | 0.170 |
Why?
|
| Cell Division | 6 | 2008 | 2711 | 0.170 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2024 | 1668 | 0.170 |
Why?
|
| Histone Demethylases | 1 | 2021 | 145 | 0.170 |
Why?
|
| Infusions, Intravenous | 11 | 2015 | 1441 | 0.170 |
Why?
|
| Granulocytes | 4 | 2014 | 243 | 0.170 |
Why?
|
| Burkitt Lymphoma | 2 | 2017 | 350 | 0.170 |
Why?
|
| Dioxolanes | 3 | 2004 | 51 | 0.170 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 716 | 0.170 |
Why?
|
| Odds Ratio | 2 | 2015 | 2335 | 0.170 |
Why?
|
| Drug Delivery Systems | 4 | 2013 | 664 | 0.170 |
Why?
|
| Karyotyping | 6 | 2015 | 1064 | 0.170 |
Why?
|
| Drugs, Generic | 1 | 2019 | 35 | 0.170 |
Why?
|
| Neoplasm Staging | 9 | 2015 | 13993 | 0.170 |
Why?
|
| Medical Oncology | 4 | 2019 | 1463 | 0.170 |
Why?
|
| Farnesyltranstransferase | 3 | 2010 | 125 | 0.170 |
Why?
|
| Nuclear Proteins | 5 | 2017 | 3472 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factors | 4 | 2003 | 249 | 0.170 |
Why?
|
| Tretinoin | 5 | 2021 | 621 | 0.160 |
Why?
|
| Pipobroman | 2 | 2020 | 2 | 0.160 |
Why?
|
| Survival | 3 | 2016 | 184 | 0.160 |
Why?
|
| Peptidomimetics | 1 | 2019 | 29 | 0.160 |
Why?
|
| Interferon-gamma | 3 | 2006 | 1180 | 0.160 |
Why?
|
| Furans | 2 | 2009 | 103 | 0.160 |
Why?
|
| Exons | 3 | 2018 | 1388 | 0.160 |
Why?
|
| Enzyme Activation | 6 | 2013 | 1832 | 0.160 |
Why?
|
| Glucocorticoids | 4 | 2022 | 620 | 0.160 |
Why?
|
| Multiple Sclerosis | 1 | 2022 | 371 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2018 | 3929 | 0.160 |
Why?
|
| Osteolysis | 1 | 2019 | 99 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2013 | 2085 | 0.160 |
Why?
|
| Bone Remodeling | 1 | 2019 | 102 | 0.160 |
Why?
|
| beta Catenin | 2 | 2020 | 691 | 0.160 |
Why?
|
| Congresses as Topic | 2 | 2019 | 296 | 0.160 |
Why?
|
| Reproducibility of Results | 7 | 2022 | 6210 | 0.150 |
Why?
|
| Quinolones | 2 | 2010 | 163 | 0.150 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 190 | 0.150 |
Why?
|
| Lymphoma, B-Cell | 2 | 2017 | 936 | 0.150 |
Why?
|
| Osteoclasts | 1 | 2019 | 158 | 0.150 |
Why?
|
| Antigens, CD | 7 | 2014 | 1436 | 0.150 |
Why?
|
| GRB2 Adaptor Protein | 1 | 2018 | 56 | 0.150 |
Why?
|
| Leukemia, T-Cell | 2 | 2009 | 90 | 0.150 |
Why?
|
| Cell Cycle | 10 | 2012 | 2150 | 0.150 |
Why?
|
| Transcription Factor RelA | 1 | 2018 | 186 | 0.150 |
Why?
|
| Hyperplasia | 1 | 2019 | 581 | 0.150 |
Why?
|
| Antiviral Agents | 3 | 2020 | 1255 | 0.150 |
Why?
|
| Itraconazole | 2 | 2009 | 81 | 0.150 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2019 | 205 | 0.150 |
Why?
|
| Neoplasm, Residual | 5 | 2021 | 1741 | 0.150 |
Why?
|
| Drug Monitoring | 3 | 2018 | 356 | 0.150 |
Why?
|
| Leukocytosis | 2 | 2014 | 115 | 0.150 |
Why?
|
| Platelet Transfusion | 1 | 2018 | 168 | 0.140 |
Why?
|
| HLA Antigens | 3 | 2019 | 588 | 0.140 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2018 | 294 | 0.140 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2022 | 1720 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2011 | 296 | 0.140 |
Why?
|
| Hepatitis C | 1 | 2022 | 551 | 0.140 |
Why?
|
| Dizziness | 2 | 2014 | 43 | 0.140 |
Why?
|
| Leukemia, Hairy Cell | 2 | 2010 | 129 | 0.140 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2016 | 41 | 0.140 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 680 | 0.140 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 2053 | 0.140 |
Why?
|
| Antigens, CD20 | 3 | 2008 | 207 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2020 | 845 | 0.140 |
Why?
|
| Alkylating Agents | 3 | 2007 | 82 | 0.140 |
Why?
|
| TOR Serine-Threonine Kinases | 4 | 2013 | 1575 | 0.140 |
Why?
|
| Drug Substitution | 1 | 2016 | 86 | 0.140 |
Why?
|
| Saliva | 1 | 2017 | 238 | 0.140 |
Why?
|
| Cells, Cultured | 8 | 2016 | 5788 | 0.140 |
Why?
|
| Mitochondrial Proteins | 1 | 2019 | 385 | 0.140 |
Why?
|
| Anticoagulants | 1 | 2022 | 792 | 0.140 |
Why?
|
| Medicare | 1 | 2022 | 934 | 0.140 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2019 | 461 | 0.140 |
Why?
|
| Neutropenia | 6 | 2010 | 1001 | 0.140 |
Why?
|
| Genotype | 5 | 2016 | 4266 | 0.140 |
Why?
|
| Adamantane | 2 | 2006 | 21 | 0.130 |
Why?
|
| Leukemia, B-Cell | 1 | 2017 | 114 | 0.130 |
Why?
|
| Hydroquinones | 2 | 2006 | 33 | 0.130 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2000 | 564 | 0.130 |
Why?
|
| Pancytopenia | 1 | 2016 | 119 | 0.130 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2017 | 1068 | 0.130 |
Why?
|
| Perception | 1 | 2018 | 351 | 0.130 |
Why?
|
| Leukemia, Prolymphocytic | 2 | 2006 | 54 | 0.130 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2019 | 621 | 0.130 |
Why?
|
| T-Lymphocytes | 5 | 2020 | 3947 | 0.130 |
Why?
|
| Azepines | 1 | 2017 | 135 | 0.130 |
Why?
|
| Anilides | 1 | 2018 | 296 | 0.130 |
Why?
|
| Suppressor of Cytokine Signaling 3 Protein | 1 | 2015 | 24 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2017 | 1212 | 0.130 |
Why?
|
| Patient Preference | 1 | 2018 | 225 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 606 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2009 | 1534 | 0.130 |
Why?
|
| Multivariate Analysis | 10 | 2017 | 4352 | 0.130 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2015 | 29 | 0.130 |
Why?
|
| Lymphocyte Activation | 2 | 2014 | 1728 | 0.130 |
Why?
|
| Tryptases | 2 | 2013 | 48 | 0.130 |
Why?
|
| Polymyxin B | 2 | 1993 | 57 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2017 | 325 | 0.130 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 273 | 0.130 |
Why?
|
| Clonal Evolution | 1 | 2017 | 251 | 0.130 |
Why?
|
| Cell Survival | 6 | 2010 | 3074 | 0.130 |
Why?
|
| Kidney | 3 | 2019 | 2267 | 0.130 |
Why?
|
| Farnesol | 1 | 2015 | 17 | 0.130 |
Why?
|
| RNA-Binding Proteins | 2 | 2022 | 1026 | 0.120 |
Why?
|
| Topoisomerase I Inhibitors | 2 | 2006 | 73 | 0.120 |
Why?
|
| Thiosemicarbazones | 2 | 2006 | 24 | 0.120 |
Why?
|
| Salicylates | 1 | 2015 | 73 | 0.120 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 3 | 2003 | 88 | 0.120 |
Why?
|
| Lipopolysaccharides | 2 | 1994 | 593 | 0.120 |
Why?
|
| Caspases | 5 | 2016 | 687 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2017 | 314 | 0.120 |
Why?
|
| raf Kinases | 1 | 2015 | 80 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 472 | 0.120 |
Why?
|
| Cell Nucleus | 2 | 2018 | 1740 | 0.120 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 721 | 0.120 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2017 | 255 | 0.120 |
Why?
|
| Mortality | 1 | 2017 | 354 | 0.120 |
Why?
|
| Proteinuria | 1 | 2015 | 166 | 0.120 |
Why?
|
| Castleman Disease | 1 | 2015 | 72 | 0.120 |
Why?
|
| Gene Expression Regulation, Leukemic | 3 | 2012 | 582 | 0.120 |
Why?
|
| Busulfan | 2 | 2020 | 786 | 0.120 |
Why?
|
| RNA Splicing | 1 | 2016 | 362 | 0.120 |
Why?
|
| Statistics, Nonparametric | 2 | 2009 | 995 | 0.120 |
Why?
|
| Leukapheresis | 1 | 2014 | 166 | 0.120 |
Why?
|
| Hypertension | 2 | 2021 | 1624 | 0.120 |
Why?
|
| Neoplasm Grading | 2 | 2016 | 1827 | 0.120 |
Why?
|
| Cytogenetics | 1 | 2014 | 152 | 0.120 |
Why?
|
| Pneumonia | 3 | 2017 | 798 | 0.120 |
Why?
|
| Boronic Acids | 2 | 2008 | 355 | 0.120 |
Why?
|
| Cell Line | 5 | 2014 | 5433 | 0.110 |
Why?
|
| MicroRNAs | 2 | 2020 | 2913 | 0.110 |
Why?
|
| Standard of Care | 1 | 2016 | 276 | 0.110 |
Why?
|
| Acenaphthenes | 1 | 2013 | 7 | 0.110 |
Why?
|
| Contraindications | 1 | 2014 | 155 | 0.110 |
Why?
|
| Interleukin-1 | 1 | 1995 | 477 | 0.110 |
Why?
|
| Erythroid Precursor Cells | 3 | 2010 | 70 | 0.110 |
Why?
|
| Endocrine System Diseases | 1 | 2014 | 91 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 5187 | 0.110 |
Why?
|
| Endpoint Determination | 1 | 2014 | 183 | 0.110 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2012 | 190 | 0.110 |
Why?
|
| Antifungal Agents | 3 | 2010 | 877 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2022 | 3671 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 9 | 2015 | 3651 | 0.110 |
Why?
|
| Spiro Compounds | 2 | 2011 | 59 | 0.110 |
Why?
|
| Equipment Design | 1 | 2017 | 1207 | 0.110 |
Why?
|
| Treatment Failure | 7 | 2017 | 1432 | 0.110 |
Why?
|
| Ribonucleotides | 1 | 2013 | 55 | 0.110 |
Why?
|
| RNA, Messenger | 8 | 2021 | 6489 | 0.110 |
Why?
|
| Sepsis | 2 | 2017 | 689 | 0.110 |
Why?
|
| Probability | 3 | 2012 | 887 | 0.110 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2015 | 320 | 0.110 |
Why?
|
| International Agencies | 1 | 2013 | 108 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2003 | 1592 | 0.110 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2000 | 1237 | 0.110 |
Why?
|
| Community Networks | 1 | 2013 | 45 | 0.110 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 690 | 0.110 |
Why?
|
| Pyrazines | 2 | 2008 | 513 | 0.110 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2014 | 174 | 0.110 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2013 | 78 | 0.100 |
Why?
|
| Camptothecin | 2 | 2006 | 538 | 0.100 |
Why?
|
| Kidney Diseases | 1 | 2018 | 732 | 0.100 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2010 | 426 | 0.100 |
Why?
|
| Forecasting | 2 | 2015 | 706 | 0.100 |
Why?
|
| Sensitivity and Specificity | 4 | 2017 | 5195 | 0.100 |
Why?
|
| Urea | 1 | 2013 | 306 | 0.100 |
Why?
|
| Receptors, TIE | 2 | 2002 | 6 | 0.100 |
Why?
|
| Decision Making | 1 | 2019 | 1243 | 0.100 |
Why?
|
| Receptor, TIE-1 | 2 | 2002 | 7 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 613 | 0.100 |
Why?
|
| Bone Marrow Transplantation | 2 | 2016 | 1772 | 0.100 |
Why?
|
| Intention to Treat Analysis | 1 | 2012 | 124 | 0.100 |
Why?
|
| Radioimmunoassay | 2 | 2002 | 209 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2019 | 2287 | 0.100 |
Why?
|
| T-Lymphocyte Subsets | 4 | 2021 | 595 | 0.100 |
Why?
|
| Resorcinols | 1 | 2011 | 25 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2006 | 673 | 0.100 |
Why?
|
| Ribonucleoproteins | 1 | 2012 | 116 | 0.100 |
Why?
|
| DNA Methylation | 7 | 2016 | 2761 | 0.100 |
Why?
|
| Protein Multimerization | 1 | 2012 | 233 | 0.100 |
Why?
|
| Patient Safety | 1 | 2017 | 655 | 0.100 |
Why?
|
| Receptors, Notch | 1 | 2014 | 377 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 2576 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2015 | 606 | 0.090 |
Why?
|
| Isoxazoles | 1 | 2011 | 79 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2016 | 1134 | 0.090 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2014 | 629 | 0.090 |
Why?
|
| Body Weight | 2 | 2014 | 1335 | 0.090 |
Why?
|
| Gene Expression Regulation | 3 | 2017 | 4200 | 0.090 |
Why?
|
| Pravastatin | 2 | 2008 | 33 | 0.090 |
Why?
|
| Injections, Subcutaneous | 3 | 2007 | 344 | 0.090 |
Why?
|
| Hemangiosarcoma | 1 | 2013 | 237 | 0.090 |
Why?
|
| Cytostatic Agents | 1 | 2010 | 3 | 0.090 |
Why?
|
| Linear Models | 1 | 2013 | 1100 | 0.090 |
Why?
|
| Safety | 5 | 2018 | 465 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2018 | 1207 | 0.090 |
Why?
|
| Janus Kinase 3 | 1 | 2010 | 47 | 0.090 |
Why?
|
| Aniline Compounds | 2 | 2022 | 206 | 0.090 |
Why?
|
| Antigens, CD34 | 3 | 2019 | 643 | 0.090 |
Why?
|
| Neoplasms, Experimental | 2 | 1998 | 790 | 0.090 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2022 | 1373 | 0.090 |
Why?
|
| Aneurysm, Infected | 1 | 2010 | 31 | 0.090 |
Why?
|
| Piperidines | 3 | 2017 | 1091 | 0.090 |
Why?
|
| Benzenesulfonates | 1 | 2010 | 196 | 0.080 |
Why?
|
| Pulmonary Aspergillosis | 1 | 2010 | 33 | 0.080 |
Why?
|
| Time | 2 | 2020 | 186 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 1501 | 0.080 |
Why?
|
| Succinates | 1 | 2009 | 28 | 0.080 |
Why?
|
| Lymphocyte Count | 2 | 2016 | 485 | 0.080 |
Why?
|
| Research | 1 | 2012 | 431 | 0.080 |
Why?
|
| Epidural Neoplasms | 1 | 2008 | 8 | 0.080 |
Why?
|
| Fibrinolytic Agents | 2 | 2020 | 303 | 0.080 |
Why?
|
| Mucositis | 1 | 2010 | 150 | 0.080 |
Why?
|
| Delphi Technique | 1 | 2010 | 275 | 0.080 |
Why?
|
| Methotrexate | 4 | 2017 | 1032 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2009 | 64 | 0.080 |
Why?
|
| Enzyme Stability | 1 | 2008 | 110 | 0.080 |
Why?
|
| Cholesterol | 2 | 2014 | 681 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2000 | 1913 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 6 | 2010 | 879 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2009 | 148 | 0.080 |
Why?
|
| Drug Evaluation | 1 | 2009 | 435 | 0.080 |
Why?
|
| Serine-Arginine Splicing Factors | 2 | 2022 | 84 | 0.080 |
Why?
|
| Erythroid Cells | 1 | 2008 | 53 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2009 | 233 | 0.070 |
Why?
|
| Trisomy | 1 | 2009 | 240 | 0.070 |
Why?
|
| Paresthesia | 1 | 2007 | 33 | 0.070 |
Why?
|
| Glycoproteins | 3 | 2006 | 792 | 0.070 |
Why?
|
| Eosinophils | 1 | 2009 | 168 | 0.070 |
Why?
|
| Diphtheria Toxin | 1 | 2007 | 83 | 0.070 |
Why?
|
| Codon | 3 | 2017 | 262 | 0.070 |
Why?
|
| Colony-Forming Units Assay | 3 | 2014 | 254 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 784 | 0.070 |
Why?
|
| Quinoxalines | 1 | 2008 | 98 | 0.070 |
Why?
|
| Neoplasm Transplantation | 5 | 2004 | 1566 | 0.070 |
Why?
|
| Drug Tolerance | 1 | 2007 | 123 | 0.070 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2008 | 123 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2012 | 519 | 0.070 |
Why?
|
| Stromal Cells | 2 | 2011 | 835 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2013 | 2866 | 0.070 |
Why?
|
| Cell Death | 2 | 2003 | 689 | 0.070 |
Why?
|
| Protein Biosynthesis | 2 | 2012 | 1035 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 771 | 0.070 |
Why?
|
| Mice, Inbred NOD | 2 | 2019 | 910 | 0.070 |
Why?
|
| Scalp | 1 | 2008 | 155 | 0.070 |
Why?
|
| Survivors | 1 | 2012 | 1025 | 0.070 |
Why?
|
| Headache | 1 | 2007 | 175 | 0.070 |
Why?
|
| Proteolysis | 2 | 2020 | 380 | 0.070 |
Why?
|
| Carboplatin | 1 | 2010 | 879 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 2010 | 347 | 0.070 |
Why?
|
| Cytochromes c | 1 | 2006 | 117 | 0.070 |
Why?
|
| Caspase Inhibitors | 1 | 2006 | 96 | 0.070 |
Why?
|
| Neutrophils | 2 | 2018 | 876 | 0.070 |
Why?
|
| Cyclosporine | 4 | 2003 | 296 | 0.070 |
Why?
|
| Mycoses | 1 | 2009 | 396 | 0.070 |
Why?
|
| Pulmonary Artery | 1 | 2010 | 521 | 0.070 |
Why?
|
| Ribosomes | 1 | 2006 | 169 | 0.070 |
Why?
|
| Immunoglobulin G | 1 | 2010 | 1140 | 0.070 |
Why?
|
| Pentostatin | 2 | 2009 | 121 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2009 | 668 | 0.060 |
Why?
|
| Weight Gain | 1 | 2009 | 474 | 0.060 |
Why?
|
| Fluorouracil | 1 | 2010 | 1988 | 0.060 |
Why?
|
| Interleukin-11 | 1 | 2005 | 38 | 0.060 |
Why?
|
| Triazoles | 1 | 2009 | 629 | 0.060 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2005 | 45 | 0.060 |
Why?
|
| NF-kappa B | 3 | 2014 | 1569 | 0.060 |
Why?
|
| Peptides, Cyclic | 1 | 2006 | 139 | 0.060 |
Why?
|
| Valproic Acid | 1 | 2006 | 276 | 0.060 |
Why?
|
| Thymus Gland | 5 | 2000 | 312 | 0.060 |
Why?
|
| Membrane Potential, Mitochondrial | 3 | 2010 | 128 | 0.060 |
Why?
|
| Societies, Medical | 3 | 2019 | 1349 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 3262 | 0.060 |
Why?
|
| Clinical Competence | 1 | 2013 | 1327 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 10 | 2000 | 7237 | 0.060 |
Why?
|
| Nausea | 4 | 2009 | 540 | 0.060 |
Why?
|
| DNA | 4 | 2005 | 3089 | 0.060 |
Why?
|
| Child | 8 | 2020 | 30499 | 0.060 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2006 | 364 | 0.060 |
Why?
|
| Terminology as Topic | 1 | 2007 | 420 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 1005 | 0.060 |
Why?
|
| Sex Factors | 1 | 2009 | 2206 | 0.060 |
Why?
|
| Mast-Cell Sarcoma | 2 | 1994 | 6 | 0.060 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1999 | 683 | 0.060 |
Why?
|
| Ribonucleotide Reductases | 1 | 2003 | 48 | 0.060 |
Why?
|
| Indazoles | 1 | 2005 | 310 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2000 | 5603 | 0.060 |
Why?
|
| Asparaginase | 2 | 2017 | 186 | 0.060 |
Why?
|
| Bee Venoms | 1 | 2003 | 9 | 0.060 |
Why?
|
| Mice, Inbred ICR | 1 | 2004 | 246 | 0.060 |
Why?
|
| Autophagy | 1 | 2010 | 922 | 0.060 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2003 | 147 | 0.060 |
Why?
|
| Bees | 1 | 2003 | 32 | 0.060 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2003 | 94 | 0.060 |
Why?
|
| Protein Kinases | 2 | 2006 | 919 | 0.050 |
Why?
|
| Injections | 1 | 2024 | 286 | 0.050 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 7476 | 0.050 |
Why?
|
| Chickenpox | 1 | 2003 | 34 | 0.050 |
Why?
|
| Herpesvirus 3, Human | 1 | 2003 | 44 | 0.050 |
Why?
|
| Drug Combinations | 3 | 2006 | 636 | 0.050 |
Why?
|
| Immunohistochemistry | 5 | 2018 | 7827 | 0.050 |
Why?
|
| Child, Preschool | 5 | 2020 | 17006 | 0.050 |
Why?
|
| Patient Outcome Assessment | 2 | 2015 | 247 | 0.050 |
Why?
|
| Uric Acid | 1 | 2023 | 121 | 0.050 |
Why?
|
| Reference Values | 2 | 2003 | 1155 | 0.050 |
Why?
|
| Herpes Zoster | 1 | 2003 | 53 | 0.050 |
Why?
|
| Glatiramer Acetate | 1 | 2022 | 13 | 0.050 |
Why?
|
| Multienzyme Complexes | 1 | 2003 | 228 | 0.050 |
Why?
|
| RNA, Neoplasm | 3 | 2013 | 810 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2003 | 190 | 0.050 |
Why?
|
| Interleukin-5 | 1 | 2022 | 69 | 0.050 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2005 | 640 | 0.050 |
Why?
|
| Off-Label Use | 1 | 2022 | 49 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 3 | 2009 | 241 | 0.050 |
Why?
|
| Pregnancy | 2 | 2020 | 8100 | 0.050 |
Why?
|
| International Cooperation | 2 | 2013 | 326 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2018 | 2035 | 0.050 |
Why?
|
| Electrophoresis, Capillary | 1 | 2001 | 34 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2006 | 514 | 0.050 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2022 | 261 | 0.050 |
Why?
|
| Cell Growth Processes | 2 | 2012 | 340 | 0.050 |
Why?
|
| Chimerism | 1 | 2021 | 65 | 0.050 |
Why?
|
| Transplantation Chimera | 1 | 2021 | 173 | 0.050 |
Why?
|
| Mice, Inbred DBA | 3 | 1996 | 119 | 0.050 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2014 | 105 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2022 | 245 | 0.050 |
Why?
|
| Self Administration | 1 | 2021 | 58 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2022 | 352 | 0.050 |
Why?
|
| Palliative Care | 3 | 2012 | 2159 | 0.050 |
Why?
|
| Phosphoproteins | 2 | 2022 | 1230 | 0.050 |
Why?
|
| Lymphoma, Follicular | 1 | 2006 | 636 | 0.050 |
Why?
|
| Benzoates | 1 | 2021 | 130 | 0.050 |
Why?
|
| Iron | 1 | 2024 | 382 | 0.050 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2006 | 749 | 0.050 |
Why?
|
| Goals | 1 | 2022 | 190 | 0.050 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 2 | 2015 | 95 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 148 | 0.040 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2020 | 41 | 0.040 |
Why?
|
| Area Under Curve | 3 | 2009 | 729 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2022 | 335 | 0.040 |
Why?
|
| Endothelial Cells | 2 | 2022 | 1048 | 0.040 |
Why?
|
| Mixed Function Oxygenases | 1 | 2020 | 68 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2021 | 1659 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 2019 | 49 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 4889 | 0.040 |
Why?
|
| Vomiting | 3 | 2007 | 361 | 0.040 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2019 | 90 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2019 | 65 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2022 | 423 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2000 | 744 | 0.040 |
Why?
|
| Tartrate-Resistant Acid Phosphatase | 1 | 2019 | 11 | 0.040 |
Why?
|
| Cathepsin K | 1 | 2019 | 15 | 0.040 |
Why?
|
| Tyrosine | 2 | 2014 | 510 | 0.040 |
Why?
|
| Acetanilides | 1 | 2018 | 17 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2005 | 1159 | 0.040 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2020 | 114 | 0.040 |
Why?
|
| Caspase 9 | 2 | 2012 | 188 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2016 | 2457 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 2013 | 835 | 0.040 |
Why?
|
| Bloodletting | 1 | 2018 | 6 | 0.040 |
Why?
|
| Government Regulation | 1 | 2018 | 59 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2021 | 834 | 0.040 |
Why?
|
| Logistic Models | 2 | 2017 | 3469 | 0.040 |
Why?
|
| Immunologic Memory | 2 | 2000 | 380 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 237 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2003 | 2106 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 153 | 0.040 |
Why?
|
| Lipopeptides | 2 | 2010 | 117 | 0.040 |
Why?
|
| Telomere | 1 | 2001 | 546 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2013 | 5690 | 0.040 |
Why?
|
| RNA Editing | 1 | 2018 | 98 | 0.040 |
Why?
|
| RNA | 1 | 2022 | 1072 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2020 | 340 | 0.040 |
Why?
|
| Adoptive Transfer | 1 | 2019 | 436 | 0.040 |
Why?
|
| Hodgkin Disease | 1 | 2006 | 1488 | 0.040 |
Why?
|
| Asthenia | 1 | 2017 | 18 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-abl | 2 | 2009 | 83 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 1248 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 2018 | 221 | 0.040 |
Why?
|
| Histones | 2 | 2020 | 1514 | 0.040 |
Why?
|
| Echinocandins | 2 | 2010 | 134 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 329 | 0.040 |
Why?
|
| Urticaria | 1 | 2017 | 28 | 0.030 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2016 | 49 | 0.030 |
Why?
|
| Dyspnea | 1 | 2020 | 421 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2018 | 2351 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2003 | 16242 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2017 | 316 | 0.030 |
Why?
|
| Cellular Microenvironment | 1 | 2016 | 36 | 0.030 |
Why?
|
| Solubility | 2 | 2007 | 251 | 0.030 |
Why?
|
| Genetic Variation | 2 | 2019 | 2157 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2016 | 201 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2006 | 286 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2009 | 243 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2020 | 908 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2017 | 255 | 0.030 |
Why?
|
| Coronary Disease | 1 | 2020 | 783 | 0.030 |
Why?
|
| Stem Cell Factor | 2 | 2008 | 88 | 0.030 |
Why?
|
| Sequence Deletion | 2 | 2011 | 915 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 2007 | 596 | 0.030 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 2015 | 56 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 353 | 0.030 |
Why?
|
| Stimulation, Chemical | 1 | 1994 | 112 | 0.030 |
Why?
|
| CD52 Antigen | 2 | 2006 | 47 | 0.030 |
Why?
|
| Benzodioxoles | 1 | 2014 | 29 | 0.030 |
Why?
|
| Phycoerythrin | 1 | 2014 | 4 | 0.030 |
Why?
|
| CD59 Antigens | 1 | 2014 | 11 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2015 | 206 | 0.030 |
Why?
|
| CD2 Antigens | 1 | 2014 | 30 | 0.030 |
Why?
|
| Infant | 2 | 2017 | 13936 | 0.030 |
Why?
|
| Genes, myc | 1 | 2016 | 375 | 0.030 |
Why?
|
| Tetraspanin 30 | 1 | 2014 | 14 | 0.030 |
Why?
|
| Etoposide | 1 | 2017 | 905 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 512 | 0.030 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2014 | 52 | 0.030 |
Why?
|
| Receptors, Complement 3b | 1 | 2014 | 20 | 0.030 |
Why?
|
| Epigenetic Repression | 1 | 2014 | 8 | 0.030 |
Why?
|
| Immunoglobulin J Recombination Signal Sequence-Binding Protein | 1 | 2014 | 18 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2015 | 242 | 0.030 |
Why?
|
| Exanthema | 1 | 2017 | 210 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 1998 | 1020 | 0.030 |
Why?
|
| Emotions | 1 | 2018 | 556 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2014 | 170 | 0.030 |
Why?
|
| Fluorescence | 1 | 1994 | 199 | 0.030 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2014 | 36 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2020 | 1327 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2017 | 331 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2015 | 201 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2014 | 246 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 2016 | 234 | 0.030 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2014 | 101 | 0.030 |
Why?
|
| Bortezomib | 2 | 2008 | 542 | 0.030 |
Why?
|
| Echocardiography | 1 | 2020 | 1241 | 0.030 |
Why?
|
| Lectins, C-Type | 1 | 2014 | 163 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2015 | 355 | 0.030 |
Why?
|
| Stem Cell Niche | 1 | 2014 | 94 | 0.030 |
Why?
|
| SEER Program | 1 | 2017 | 1047 | 0.030 |
Why?
|
| Purines | 1 | 2014 | 275 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2016 | 1077 | 0.030 |
Why?
|
| TYK2 Kinase | 1 | 2012 | 9 | 0.030 |
Why?
|
| Organ Dysfunction Scores | 1 | 2013 | 70 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 736 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2014 | 316 | 0.030 |
Why?
|
| Base Sequence | 2 | 2012 | 5500 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 1409 | 0.030 |
Why?
|
| Reactive Oxygen Species | 2 | 2009 | 1011 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2015 | 1904 | 0.030 |
Why?
|
| Peritoneal Cavity | 1 | 1992 | 58 | 0.030 |
Why?
|
| Testis | 2 | 2006 | 753 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2020 | 1699 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 1994 | 1041 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 408 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2016 | 1470 | 0.020 |
Why?
|
| HL-60 Cells | 1 | 2012 | 318 | 0.020 |
Why?
|
| Spliceosomes | 1 | 2012 | 76 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2013 | 946 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2017 | 882 | 0.020 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2013 | 272 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 1995 | 692 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 255 | 0.020 |
Why?
|
| Chromosome Banding | 1 | 2011 | 280 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2011 | 199 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 502 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 7791 | 0.020 |
Why?
|
| Aging | 1 | 2019 | 1578 | 0.020 |
Why?
|
| Age Distribution | 1 | 2012 | 730 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 1146 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1606 | 0.020 |
Why?
|
| Femur | 1 | 2011 | 162 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2010 | 84 | 0.020 |
Why?
|
| Clindamycin | 1 | 2010 | 52 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2007 | 895 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2008 | 3417 | 0.020 |
Why?
|
| Ofloxacin | 1 | 2010 | 43 | 0.020 |
Why?
|
| CD13 Antigens | 1 | 2010 | 43 | 0.020 |
Why?
|
| CD56 Antigen | 1 | 2010 | 85 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 4371 | 0.020 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2010 | 124 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2013 | 706 | 0.020 |
Why?
|
| Acyclovir | 1 | 2010 | 80 | 0.020 |
Why?
|
| Cell Size | 1 | 2010 | 145 | 0.020 |
Why?
|
| Quinolines | 1 | 2013 | 403 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2010 | 116 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 1085 | 0.020 |
Why?
|
| Killer Cells, Lymphokine-Activated | 2 | 2000 | 55 | 0.020 |
Why?
|
| Fluconazole | 1 | 2010 | 109 | 0.020 |
Why?
|
| Lymph Nodes | 2 | 2015 | 3080 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2013 | 957 | 0.020 |
Why?
|
| Ceftazidime | 1 | 2010 | 66 | 0.020 |
Why?
|
| Valine | 1 | 2010 | 184 | 0.020 |
Why?
|
| Inflammation | 1 | 2019 | 2534 | 0.020 |
Why?
|
| Voriconazole | 1 | 2009 | 115 | 0.020 |
Why?
|
| Exome | 1 | 2014 | 1252 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 1322 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2014 | 1055 | 0.020 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2009 | 157 | 0.020 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2009 | 109 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 2029 | 0.020 |
Why?
|
| Aspergillus | 1 | 2010 | 152 | 0.020 |
Why?
|
| Mouth | 1 | 2010 | 125 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 3 | 2010 | 3176 | 0.020 |
Why?
|
| Orbital Neoplasms | 1 | 2011 | 237 | 0.020 |
Why?
|
| Bilirubin | 1 | 2009 | 224 | 0.020 |
Why?
|
| Anthracyclines | 1 | 2010 | 339 | 0.020 |
Why?
|
| Amphotericin B | 1 | 2010 | 304 | 0.020 |
Why?
|
| Abscess | 1 | 2010 | 192 | 0.020 |
Why?
|
| Age of Onset | 1 | 2010 | 852 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 3026 | 0.020 |
Why?
|
| Meninges | 1 | 2008 | 48 | 0.020 |
Why?
|
| Back | 1 | 2008 | 49 | 0.020 |
Why?
|
| Receptors, Erythropoietin | 1 | 2008 | 76 | 0.020 |
Why?
|
| Mercaptopurine | 1 | 2008 | 131 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 1397 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2008 | 178 | 0.020 |
Why?
|
| Leukemic Infiltration | 1 | 2008 | 73 | 0.020 |
Why?
|
| Half-Life | 1 | 2008 | 269 | 0.020 |
Why?
|
| Ataxia | 1 | 2009 | 183 | 0.020 |
Why?
|
| Kinetics | 2 | 2001 | 2242 | 0.020 |
Why?
|
| Oxygen | 1 | 2012 | 800 | 0.020 |
Why?
|
| Necrosis | 2 | 2003 | 604 | 0.020 |
Why?
|
| Vancomycin | 1 | 2010 | 292 | 0.020 |
Why?
|
| Metaphase | 1 | 2007 | 124 | 0.020 |
Why?
|
| Classification | 1 | 2007 | 40 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 2011 | 5330 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2007 | 32 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2005 | 1054 | 0.020 |
Why?
|
| Protamines | 1 | 2006 | 29 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 7929 | 0.020 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2007 | 44 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2008 | 593 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2010 | 829 | 0.020 |
Why?
|
| Melphalan | 1 | 2010 | 875 | 0.020 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2006 | 18 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2013 | 1190 | 0.020 |
Why?
|
| DNA Probes | 1 | 2007 | 248 | 0.020 |
Why?
|
| U937 Cells | 1 | 2006 | 179 | 0.020 |
Why?
|
| Anemia, Myelophthisic | 1 | 2006 | 5 | 0.020 |
Why?
|
| Basophils | 1 | 2006 | 45 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2007 | 253 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2011 | 1066 | 0.020 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2006 | 95 | 0.020 |
Why?
|
| Cranial Irradiation | 1 | 2008 | 322 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2006 | 320 | 0.020 |
Why?
|
| Topotecan | 1 | 2007 | 248 | 0.020 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2006 | 105 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2006 | 135 | 0.020 |
Why?
|
| Cell Count | 1 | 2007 | 524 | 0.020 |
Why?
|
| K562 Cells | 1 | 2006 | 345 | 0.020 |
Why?
|
| Placenta Growth Factor | 1 | 2005 | 25 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2006 | 341 | 0.020 |
Why?
|
| Matrix Metalloproteinases | 1 | 2006 | 139 | 0.020 |
Why?
|
| Protein Transport | 1 | 2008 | 739 | 0.020 |
Why?
|
| Pregnancy Proteins | 1 | 2005 | 43 | 0.020 |
Why?
|
| CD146 Antigen | 1 | 2005 | 57 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2006 | 735 | 0.020 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2005 | 54 | 0.020 |
Why?
|
| Transfection | 1 | 2011 | 3166 | 0.020 |
Why?
|
| Fungemia | 1 | 2006 | 119 | 0.020 |
Why?
|
| Base Pair Mismatch | 1 | 2005 | 82 | 0.020 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2005 | 72 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2005 | 109 | 0.020 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2007 | 289 | 0.020 |
Why?
|
| Blood Coagulation Disorders | 1 | 2007 | 116 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2008 | 522 | 0.020 |
Why?
|
| Disabled Persons | 1 | 2007 | 112 | 0.020 |
Why?
|
| Myeloid Cells | 1 | 2007 | 277 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2006 | 296 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2005 | 180 | 0.020 |
Why?
|
| Gene Library | 1 | 2006 | 355 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 170 | 0.020 |
Why?
|
| Tubulin | 1 | 2005 | 203 | 0.020 |
Why?
|
| Ligands | 1 | 2008 | 1057 | 0.020 |
Why?
|
| Leukocyte Common Antigens | 1 | 2005 | 192 | 0.020 |
Why?
|
| Acetylation | 1 | 2006 | 517 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2006 | 452 | 0.020 |
Why?
|
| Chromosome Inversion | 1 | 2005 | 197 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2009 | 522 | 0.020 |
Why?
|
| Lymphocytes | 2 | 2003 | 1280 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 1994 | 1841 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2007 | 860 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2005 | 176 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2014 | 5841 | 0.010 |
Why?
|
| Constipation | 1 | 2005 | 184 | 0.010 |
Why?
|
| Data Collection | 1 | 2007 | 624 | 0.010 |
Why?
|
| Microtubules | 1 | 2005 | 330 | 0.010 |
Why?
|
| Deoxyadenine Nucleotides | 1 | 2003 | 29 | 0.010 |
Why?
|
| Deoxyguanine Nucleotides | 1 | 2003 | 22 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 1133 | 0.010 |
Why?
|
| DNA Primers | 1 | 2006 | 1513 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2007 | 559 | 0.010 |
Why?
|
| Mice, Inbred CBA | 1 | 2003 | 83 | 0.010 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2003 | 138 | 0.010 |
Why?
|
| Therapies, Investigational | 1 | 2003 | 60 | 0.010 |
Why?
|
| Pharmacokinetics | 1 | 2003 | 40 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2004 | 225 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2006 | 1718 | 0.010 |
Why?
|
| I-kappa B Proteins | 1 | 2003 | 177 | 0.010 |
Why?
|
| Hyperbilirubinemia | 1 | 2003 | 79 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 2003 | 148 | 0.010 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2004 | 265 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1999 | 4797 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 718 | 0.010 |
Why?
|
| Motor Activity | 1 | 2007 | 718 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 2010 | 948 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2004 | 322 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 2003 | 240 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2006 | 815 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2003 | 265 | 0.010 |
Why?
|
| Internet | 1 | 2007 | 701 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2002 | 233 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2003 | 330 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 2001 | 106 | 0.010 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2003 | 249 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2003 | 719 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2006 | 967 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2002 | 593 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2003 | 599 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2005 | 1756 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2008 | 1340 | 0.010 |
Why?
|
| Bacteremia | 1 | 2006 | 722 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2006 | 4635 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2004 | 1132 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 1483 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2002 | 1742 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 852 | 0.010 |
Why?
|
| Mitochondria | 1 | 2006 | 1314 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2003 | 2337 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 6782 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 2003 | 485 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2004 | 1014 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2004 | 1102 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2000 | 442 | 0.010 |
Why?
|
| Binding Sites | 1 | 2002 | 2298 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2003 | 1972 | 0.010 |
Why?
|
| DNA Repair | 1 | 2005 | 1912 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2003 | 1429 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 5213 | 0.010 |
Why?
|
| Esophageal Neoplasms | 1 | 2010 | 3240 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1994 | 91 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 1994 | 71 | 0.010 |
Why?
|
| Graft Rejection | 1 | 1995 | 865 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2006 | 5996 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 12012 | 0.000 |
Why?
|